baber/WOPTO huggingface dataset:
Patent NZ-569078-A (NZ)
Title: Annexin derivatives suitable for pretargeting in therapy and diagnosis
Inventor: REUTELINGSPERGER CHRISTIAAN PETER MARIA
IPC: A61K47/42
Filed: 2006-12-12
Abstract: Disclosed is an annexin variant corresponding to annexin A5 having the ammo acid sequence of SEQ ID NO: 1: a) that binds to at least one phospholipid; b) that is not internalized into a cell, wherein one or more amino acids selected from polar amino acids Glu, GIn, Asp, Asn, Arg and Lys in the helices IA, ID, IIA, IID, IIIC, IIID and IVE and in the stretches connecting helices IC and ID, IIE and IIIA, IIIC and IIID, IIID and IIIE, and IVA and IVB are replaced by non-polar amino acids; c) that is bound to a recognizable compound through a cysteine residue of the annexin variant. Also disclosed is an annexin variant wherein the annexin comprises SEQ ID NO: 1 for annexin A5 or the corresponding sequences for other annexins, wherein one or more amino acids selected from Glu, GIn, Asp, Asn, Arg, Lys and His at positions 16-29, 59-74, 88-102, 135-145, 156-169, 202-231, 259-266 and 305-317, or the corresponding sequences for other annexins, are replaced by Gly, Ala, Val, lIe, Leu, Ser, Thr, Met, Pro, Phe, or Tyr, and wherein one of the amino acids at positions 1-19, 24, 28,46-64, 86-89, 118-135, 149-150, 157-170, 203-219, 245-248 and 280-294 has been replaced by a cysteine residue, which is optionally substituted.
Patent NZ-581871-A (NZ)
Title: Controlling transmit power by including power offset value in feedback signal from user device
Inventor: CELEBI SAMEL
IPC: H04B7/005
Filed: 2008-06-30
Abstract: Disclosed is a wireless communications apparatus that enables selective modification of broadcast information within a wireless communications environment. The apparatus has means for identifying incorrect information included in a signal from an access point and means for determining a recommended modification for the incorrect information (604). The apparatus further contains means for sending the recommended modification in a feedback signal to the access point (606) and means for receiving a request from the access point to verify at least a portion of the information included in the signal. Also included is means for providing a result of the verification to the access point.
Patent NZ-583144-A (NZ)
Title: Sealant compositions and methods of use
Inventor: RAVI KRISHNA M
IPC: C09K8/03
Filed: 2008-08-05
Abstract: Disclosed is a sealant composition comprising a base fluid, a binder material present in an amount of 0.25 percent to 10 percent by weight of the slurry, and a filler material, wherein: the binder material comprises at least one material selected from the group consisting of fly ash, hydrated lime, fume silica, a pozzolanic material, and a cementitious material; and the filler material comprises at least one material selected from the group consisting of sand, barite, calcium carbonate, ground marble, iron oxide, manganese oxide, glass bead, crushed glass, crushed drill cutting, ground vehicle tire, crushed rock, ground asphalt, crushed concrete, crushed cement, salt, ilmenite, hematite, an elastomer, a polymer, diatomaceous earth, a highly swellable clay miner, and a fiber; and the sealant composition forms a cohesive sealant that yields when subjected to pressure and stresses of the wellbore. Also disclosed is a method for introducing the above mentioned sealant into a well bore.
Patent NZ-584279-A (NZ)
Title: Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
Inventor: MAIER THOMAS
IPC: A61K31/4365
Filed: 2008-09-19
Abstract: Tetrahydrofusedpyridine compounds of formula (I) and their salts are disclosed, in which A, B, L, D and E have meanings as given in the description these compounds are effective inhibitors of histone deacetylases and are uses for treating, preventing or ameliorating diseases such as benign and/or malignant neoplasia including cancer, arthropathies and osteopathological conditions, autoimmune diseases including transplant rejection, acute and chronic inflammatory diseases, hyperprolifera- tive diseases or neuropathological disorders which are responsive or sensitive to inhibition of histone deacetylase activity.
Patent NZ-584971-A (NZ)
Title: Process for the preparation of zolmitriptan, salts and solvates thereof
Inventor: DATTA DEBASHISH
IPC: A61K31/4178
Filed: 2008-10-03
Abstract: Disclosed is a process for the preparation of zolmitriptan (I), comprising:(a) diazotization of (S)-4-(4-aminobenzyl)-1 ,3-oxazolidin-2-one, or a protected form thereof, to form a diazonium intermediate, followed by reduction of the diazonium intermediate using stannous chloride to give (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one, or a protected form thereof (b) condensation of (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one, or a protected form thereof, with 4-N,N-dimethylamino-butyraldehyde, or a protected form thereof, to form a hydrazone intermediate, or a protected form thereof; and (c) cyclisation of the resultant hydrazone intermediate to yield zolmitriptan (I) wherein none of the intermediates are isolated.
Patent NZ-585407-A (NZ)
Title: Device and method for preparing microparticles
Inventor: BHANDARI BHESH
IPC: A23L27/00
Filed: 2008-11-14
Abstract: A method for preparing micro-particles is disclosed, which comprises contacting within the body of a reaction chamber a first cross-linkable reagent (preferably an alginate) in aerosol form with a second cross-linking reagent (preferably a divalent or trivalent cation, such as calcium chloride (CaCl2) in aerosol form to thereby form microparticles, wherein formation of the micro-particles takes place by a sol-gel phase transition associated with the cross-linkable reagent. The disclosure also relates to a reactor adapted for implementing said method, wherein the reactor comprising a reaction chamber body comprising a first atomiser for introducing an aerosol of a cross-linkable reagent into the body of the reaction chamber, and a second atomiser for introducing an aerosol of a cross-linking reagent into the body of the reaction chamber. Suitable atomisers include nozzles that rely on centrifugal, kinetic, pressure or sonic energy. Preferred atomisers include pneumatic and ultrasonic atomisers.
Patent NZ-592965-A (NZ)
Title: Colored and laminated metal plate for container
Inventor: YASUE YOSHIHIKO
IPC: C09J7/29
Filed: 2009-11-12
Abstract: Disclosed is a coloured laminated metal plate for containers, comprising a metal plate having one or both surfaces coated with a film for lamination in which a coloured adhesive layer is coated to a polyester resin film, wherein the coloured adhesive layer contains a polyester resin as a main component and further contains an etherified amino resin, an epoxy resin, a strong acid compound, and a colouring agent.
Patent NZ-599526-A (NZ)
Title: Gene knockout mesophilic and gene knockout mesophilic and thermophilic organisms, and methods of use thereof
Inventor: HOGSETT DAVID A
Filed: 2012-04-20
Abstract: Disclosed is a genetically modified thermophilic or mesophilic microorganism, wherein a first native gene is partially, substantially, or completely deleted, silenced, inactivated, or down-regulated, which first native gene o encodes a first native enzyme involved in the metabolic production of an organic acid or a salt thereof, thereby increasing the native ability of said thermophilic or mesophilic microorganism to produce ethanol as a fermentation product. In certain embodiments, the aforementioned microorganism further comprises a first non-native gene, which first non- native gene encodes a first non-native enzyme involved in the metabolic production of ethanol.
Patent NZ-601864-A (NZ)
Title: Method of tolling vehicles in an open-road toll system
Inventor: BOSZORMENYI ADAM
IPC: G06Q20/26
Filed: 2012-08-16
Abstract: A method of tolling vehicles in an open-road toll system with vehicle-based on-board units that are able to communicate with roadside radio beacons via short-range radio interfaces is disclosed. The on-board units comprises a first memory for an electronic toll credit account, a second memory for a transaction information concerning a last debit to the toll credit account, and a third memory for a variable factor, and the radio beacons sending requests for debiting a debit amount to the toll credit account to passing on-board units. The method comprises the following steps that are carried out as an on-board unit passes a toll beacon: reading out the transaction information from the second memory and the factor from the third memory of the on-board unit via the radio interface into the toll beacon; updating the factor as a function of the read-out- transaction information and calculating a debit amount as a function of the updated factor in the toll beacon; sending a debit request with the calculated debit amount and the updated factor from the toll beacon via the radio interface to the on-board unit; and debiting the received debit amount to the toll credit account in the first memory and writing a new transaction information concerning this new debit transaction into the second memory and the received updated factor into the third memory of the on-board unit. Also disclosed is a method of tolling vehicles in an open-road toll system with vehicle-based on-board units that are able to communicate with roadside radio beacons via short-range radio interfaces. The on-board units comprises a first memory for an electronic toll credit account, a second memory for a transaction information concerning a last debit to the toll credit account, and a third memory for a variable factor, and the radio beacons sending requests for debiting a debit amount to the toll credit account to passing on-board units. The method comprises the following steps that are carried out as an on-board unit passes a toll beacon: reading out the toll credit account from the first memory, the transaction information from the second memory and the factor from the third memory of the on-board unit via the radio interface into the toll beacon; updating the factor as a function of the read-out transaction information and calculating a debit amount as a function of the updated factor and debiting the debit amount to the read-out toll credit account in the toll beacon; sending the thus updated toll credit account and the updated factor from the toll beacon via the radio interface to the on-board unit; and writing the received updated toll credit account into the first memory, a new transaction information concerning this new debit transaction into the second memory and the received updated factor into the third memory of the on-board unit.
Patent NZ-603964-A (NZ)
Title: Biodegradable polymer - bioactive moiety conjugates
Inventor: O’SHEA MICHAEL SHANE
IPC: A61K47/34
Filed: 2009-10-09
Abstract: Disclosed is a biodegradable polymer comprising a polyester component, the biodegradable polymer prepared by polymerising a diol monomer - bioactive moiety conjugate of formula (II) with at least one selected from the group consisting of: (i) an alkyl ester of lysine diisocyanate; and (ii) a polyisocyanate in the presence of one or more polyester polyol co-monomers, wherein the variables X’, Y’, R, Z and D are as defined in the specification.
Patent NZ-611654-A (NZ)
Title: Treatment of jak2-mediated conditions
Inventor: SMITH GREGG DAVID
IPC: A61P7/06
Filed: 2011-11-29
Abstract: Provided is a method for treating a patient with anaemia, comprising the administration of N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide (CYT387 or momelotinib) or a related pyrimidine containing compound of the general formula (1) where the variables are defined in the specification. An example of a related compound is 4-(5-bromo-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide. Further provided are an article of manufacture and a kit comprising CYT387 with a label or instructions related to the use of CYT387 in anaemia. Provided is an improved method for treating a subject having, or at risk of, a medical condition for which a JAK inhibitor is indicated, the method comprising selecting a subject that meets at least one of a number of criteria and administering CYT387 whereby the treated subject exhibits an anaemia and/or a spleen response that is improved relative to a subject not meeting any of the criteria. Further provided are an article of manufacture and a kit comprising CYT387 and a label or instructions related to the use of CYT387 in relation to the criteria of the improved method.
Patent NZ-627853-A (NZ)
Title: Apparatus for heat shrinking a package and method for heat shrinking a package
Inventor: STEINER ANDRE
IPC: F28D21/00
Filed: 2013-02-06
Abstract: An apparatus and method for heat-shrinking food packages such as meat or cheese using hot water is described. The apparatus seeks to improve contact of the heat shrink on the package by providing a hot environment during shrinking, and to improve energy efficiency by using rising vapour to heat the hot water in the overhanging heating container. The package (2) moves through the heated chamber (10) and is heat shrunk by steam (12) from sprayers (13) that receive the steam from a tank (30) that is from the heated container above (20). The steam recirculates and heats the water in the heated container (20).
Patent NZ-630166-A (NZ)
Title: Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
Inventor: SAMPATH DEEPAK
IPC: A61P35/02
Filed: 2013-09-06
Abstract: Disclosed is a use of a GA101 antibody and/or 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide (GDC-0199) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a human, said treatment comprising co-administering an effective amount of said GA101 antibody and GDC-0199 or a pharmaceutically acceptable salt thereof for one or more dosing periods followed by one or more dosing periods where (i) an effective amount of the GDC-0199 or a pharmaceutically acceptable salt thereof is administered alone in the absence of the GA101 antibody, or (ii) an effective amount of the GA101 antibody alone is administered in the absence of the GDC-0199 or a pharmaceutically acceptable salt thereof.
Patent NZ-630569-A (NZ)
Title: Process for the purification of diaminophenothiazinium compounds
Inventor: EUTICK MALVIN
IPC: C07D279/20
Filed: 2014-08-15
Abstract: Disclosed is a process for the purification of a diaminophenothiazinium compound including the steps of: (i) contacting the diaminophenothiazinium compound with a reducing agent to form a protonated stabilised diaminophenothiazinium complex; (ii) purifying the protonated stabilised diaminophenothiazinium complex; and (iii) contacting the purified protonated stabilised diaminophenothiazinium complex with an oxidising agent to convert it back to the diaminophenothiazinium compound, to thereby purify the diaminophenothiazinium compound. In a particular embodiment, the diaminophenothiazinium compound is selected from the group consisting of methylene blue, methylene green, Azure A, Azure B and Azure C.
Patent NZ-631132-A (NZ)
Title: Exon skipping compositions for treating muscular dystrophy
Inventor: DIANE ELIZABETH FRANK
IPC: C12N15/113
Filed: 2014-03-14
Abstract: Disclosed is an antisense oligomer having the sequence GTTGCCTCCGGTTCTGAAGGTGTTC (SEQ ID NO: 1) wherein the bases of said oligomer are linked to morpholino ring structures and wherein said morpholino ring structures are joined by phosphorous-containing intersubunit linkages joining a morpholino nitrogen of one ring structure to a 5’ exocyclic carbon of an adjacent ring structure, and wherein the oligomer specifically hybridises to an exon 53 target region H53A (+36+60) and induces exon skipping in the human dystrophin gene. Also disclosed is the treatment of Duchenne’s muscular dystrophy or Becker’s muscular dystrophy using said oligomer.
Patent NZ-701099-A (NZ)
Title: Ketol-acid reductoisomerase enzymes and methods of use
Inventor: O’KEEFE DANIEL P
IPC: C12P7/16
Filed: 2013-05-10
Abstract: Provided herein are polypeptides having ketol-acid reductoisomerase activity as well as microbial host cells comprising such polypeptides. Polypeptides provided herein may be used in biosynthetic pathways, including, but not limited to, isobutanol biosynthetic pathways.
Patent NZ-703174-A (NZ)
Title: Device for the contamination-free filling of a tank from a canister
Inventor: OESER JÖRG
IPC: F17C13/04
Filed: 2013-06-28
Abstract: Disclosed is a device for the contamination-free filling of a tank from a canister, comprising a. a tank adapter having - a tank fastening flange for fastening to the tank and - a first coupling part, further having - a closable connecting conduit; b. a canister adapter having - a canister fastening flange for fastening to the canister and - a second coupling part, further having - a closing piston which is guided in the canister adapter, the tank adapter and the canister adapter being detachably interconnected via the first and the second coupling parts, and the closing piston having a first contact face which is operationally connected to a second contact face provided on the tank adapter when the second coupling part of the canister adapter is coupled to the first coupling part of the tank adapter; further comprising c. a flushing connection for supplying cleaning fluid, which is arranged on the tank adapter and which is connected to the closable connecting conduit; wherein - the device establishes a fluid connection between the canister fastening flange and the tank fastening flange in an open position and closes the fluid connection between the canister fastening flange and the tank fastening flange in a closed position, and wherein - the second contact face can be raised from the first contact face, while the second coupling part of the canister adapter is coupled to the first coupling part of the tank adapter.
Patent NZ-706026-A (NZ)
Title: Cloud and smartphone communication system and method
Inventor: AHEARN JOHN ROBERT
IPC: H04B7/00
Filed: 2013-08-16
Abstract: A method, system or server for updating a reader device with access control information comprising transmitting a reader device identifier from a reader device to a mobile device via a wireless connection; receiving the reader device identifier at a server from the mobile device; determining, via the server, updated access control information for the reader device to receive based on an analysis of the reader device identifier, wherein the updated access control information is stored in a database at the server and includes a firmware update and a user database for the reader device; transmitting the updated access control information from the server to the mobile device for storage in the mobile device; sending the updated access control information stored in the mobile device to the reader device; sending a confirmation from the reader device to the mobile device that the updated access control information was received by the reader device, and further comprising sending a status information for the reader device from the reader device to the mobile device; and sending the confirmation and the status information from the mobile device to the server.
Patent NZ-710417-A (NZ)
Title: Paint container
Inventor: KHOURY EDWARD JOSEPH
IPC: B65D23/06
Filed: 2014-02-13
Abstract: A paint container (10) comprising a main body (12) for receiving paint wherein the main body comprises a side wall (16) and an outwardly tapering rim portion (18) at an upper end of the side wall (16). A tubular A paint container (10) comprising a main body (12) for receiving paint wherein the main body comprises a side wall (16) and an outwardly tapering rim portion (18) at an upper end of the side wall (16). A tubular member (14) is provided, a lower end of which is receivable within the rim portion (18). First connectors (26) are provided on an outer surface of the tubular member (14) and second connectors (27) are provided on an inner surface (30) of the rim portion (18). Each of the first connectors (26) engages with a corresponding one of the second connectors (27) such that the tubular member (14) is supported within the rim portion (18) to define an annular aperture between the lower end of the tubular member (14) and the main body (12) of the paint container (10). The annular aperture is provided to allow paint which has run down the outside of the tubular member (14) to easily flow back into the body 12 of the paint container (10).
Patent NZ-717741-A (NZ)
Title: Underwater noise abatement panel and resonator structure
Inventor: WILSON PRESTON
IPC: E04B9/00
Filed: 2014-09-24
Abstract: A system for reducing noise emissions in underwater environments is presented. The system can be extended to applications in any two-fluid environments where one fluid (gas) is contained in an enclosed resonator volume connected to the outside environment at an open end of the resonator body. The resonators act as gas-containing (e.g., air) Helmholtz resonators constructed into solid panels that are submerged in the fluid medium (e.g., sea water) in the vicinity of a noise generating source. The oscillations of the trapped air volume in the resonators causes reduction of certain noise energy and a general reduction in the transmitted noise in the environment of the system. The inventive concept of this apparatus is that the volume and geometry of each resonator cavity varies according to a respective design depth of deployment of said resonator cavity in a liquid. The inventive concept allows the panel to reduce noises in a range of frequencies.
Patent NZ-726959-A (NZ)
Title: Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
Inventor: KWON SE CHANG
IPC: A61K38/28
Filed: 2015-05-29
Abstract: The present invention relates to a composition for preventing or treating diabetes, containing long-acting insulin analog and long-acting insulin secretion peptide conjugates, and a method for treating diabetes. More specifically, the composition can remarkably improve compliance by inhibiting weight gain caused by the administration of insulin, inhibiting emesis and nausea phenomena caused by the administration of an insulin secretion peptide and reducing the dose of insulin through the concomitant administration of the long-acting analog conjugate and the long-acting insulin secretion peptide conjugate. In addition, the present invention relates to: a pharmaceutical composition for alleviating the side effects of pancreatic beta cells in a patient with diabetes, containing a long-acting insulin analog conjugate and a long-acting insulin secretion peptide conjugate; and a method for alleviating the side effects of pancreatic beta cells in a patient with diabetes, comprising a step of administering the composition, wherein side effects, particularly those such as pancreatic beta cell dysfunction, pancreatic beta cell reduction, lipotoxicity and glucotoxicity, which are caused by the progression of diabetes, are alleviated.
Patent NZ-738463-A (NZ)
Title: Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
Inventor: LI CHAN-JUNG
IPC: A61K31/485
Filed: 2016-05-27
Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.